Journal of Medical Sciences · 2018 · 10 citations · 25 references
MedicineHematologyOncologyChemotherapyHematologic OncologyMolecular OncologyChemotherapy In Hematologic MalignanciesHematologic MalignanciesHematologic Malignancy TherapyLymphoid NeoplasmsLymphoid TumorsGene Expression AtlasesHistopathological SubtypesLymphoma ChemotherapyNon-hodgkin Lymphoma TherapyNon-hodgkin Lymphoma Treatment
Diffuse large B cell lymphoma (DLBCL) is the most common histologic subtype of non-Hodgkin lymphoma (NHL) accounting for approximately 30 percent of all NHL cases, involving both nodal and extra-nodal sites. Apart from distinct morphological and clinicopathological subtypes, DLBCL can be dived into molecular subtypes, Germimal Centre Subtype (GCB) and Activated B-Cell (ABC) based on gene expression profiling. IPI (International Prognostication Index) and its variants are used to prognosticate the patients. Limited stage DLBCL is primarily treated with combined modality therapy consisting of abbreviated systemic chemotherapy (three cycles), and involved field radiation therapy, whereas advanced stage disease is treated with full course of chemotherapy with recommendation of addition of novel agents (Bortezomib, Ibrutinib, Lenalidomide) in ABC type DLBCL.
25
A Predictive Model for Aggressive Non-Hodgkin's Lymphoma
New England Journal of Medicine · 1993 · 5K citations · Full text
Medicine, Oncology, Chemotherapy +15
Michael Pfreundschuh, Lorenz Trümper, Anders Österborg et al. · The Lancet Oncology · 2006 · 2.1K citations
Medicine, Oncology, Chemotherapy +11